Immunology and Immunotherapy for Pancreatic Cancer: Rienk Offringa, Katelyn T. Byrne, and Jashodeep Datta will address this topic in a plenary at the AACR Conference on Advances in Pancreatic Cancer Research (Sept 15-18, Boston). bit.ly/4dTJUCb #AACRpan24 Jash Datta, MD

If test scores are what determine who is a good surgeon, then next time you need your gall bladder removed or heart surgery, please ask a dermatologist to do it. After all, we have the highest USMLE scores.

Pancreatic cancer has historically been difficult to diagnose early, but there is hope on the horizon. Scientists have developed a blood test that can accurately detect early-stage #PancreaticCancer, according to results from a large study. go.nih.gov/JDvWoix #NCRM24

Surgery vs ablation for small-size CRC liver mtes at #ASCO24 🔎COLLISION phase III, 300 pts 👉medien size 14mm, 2mets 👉mOS: no difference 👉similar local control 👉reduced morbidity & mortality in ablation arm 🧐Ablation very valid option ESMO - Eur. Oncology ILCA EASLnews

🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves

#SITC is thrilled to introduce a new #SCION travel award for standout participants focused on pancreatic cancer! The recipient will get travel reimbursement and free SCION 2025 registration. Apply by July 22, 2024 at go.sitcancer.org/4cAoQjC #immunotherapy PanCAN

Neoadjuvant nivolumab plus ipilimumab results in a substantial pathological response in most patients with mismatch repair–deficient colon cancer and appears to be safe. Read the full NICHE-2 phase 2 study results: nej.md/3Ku4X0H

This is a great opportunity to advance your knowledge in designing clinical trials in oncology and in particular for those who focus on pancreatic cancer research

From JAMA: USPSTF recommends all women undergo routine #breastcancer screening every other year beginning at age 40, an update from the 2016 recommendation to start at age 50. ja.ma/45mG9BB

All right! Abstract submission site for #ASC2025 is open. Time to start drafting your best work for submission is now!! academicsurgicalcongress.org/abstracts/ Assoc4AcademicSurgery Society of University Surgeons (SUS) Genevieve Boland, MD, PhD Callisia Clarke MD Tom Varghese Jr. MD, MS, MBA, FACS, MAMSE 🇺🇸 Luke Funk, MD, MPH @FabianJohnston Brenessa Lindeman, MD, MEHP Ankush Gosain

Join the SSO Research Committee for an upcoming session on transforming ideas from "back of a napkin" into impactful cancer care! Learn about grants, funding strategies, and staying at the cutting edge of research! Register: ow.ly/5ccl50SRjpt

PANDAS-PRODIGE 44 mFOLFIRINOX +/- chemoRT (50.4 Gy) in borderline resectable pancreas cancer. No dif in R0 resection (1 endpt) or OS for all comers…but pCR for chemoRT group was 29% (vs. 8%) & OS improved w chemoRT for pts undergoing resection (48 vs. 36 months). #ESMO24

“There are not, and will never be, KRAS inhibitors” 👀 PascaLab presents a memorable reviewer comment from her 1st unfunded NIH grant at #AACRPan24. The lesson is that you should not let deflating reviewer comments define the value of your science. Also, persistence!

📅 Upcoming webinar! Join us to learn essential strategies for negotiating academic research or surgeon-scientist positions! Gain tips on securing protected research time, financial & non-financial resources, and more. Don’t miss out: ow.ly/hhmC50ToyBo

Liver transplantation + CTx vs CTx in unresectable CRC liver metastases 🔎TransMet randomised trial The Lancet doi.org/10.1016/S0140-… 👉5-yr OS: 56.6 vs 12.6% 👉Recurrence after LTx: 72% 🧐Impressive study, impressive results ❗️LTx valid option in highly selected pts ESMO - Eur. Oncology

I see patients from all socioeconomic strata Many of them come to my oncology clinic to confront their own mortality No matter how much money you have, the ultimate currency is time Which is why it makes me so angry when insurers INTENTIONALLY waste the most precious resource

Disinformation is the biggest threat of our generation. While science should be the harshest and most honest critique of its own, we should all stand up to the smear campaigns targeted for political gains.

Featured: The authors eport the long-term survival of patients with appendiceal mucinous neoplasm undergoing cytoreduction and HIPEC randomized to oxaliplatin or mitomycin C who were included in the trial. ow.ly/oL8I50UG9Zo Syed A. Ahmad

It may succeed. It might not. It might open the doors for more effective approaches in future. But when you say it “will” fail before the studies are even conducted you will lose your scientific credibility

The Joint Committee Conference was a success. Our leaders and volunteers were hard at work planning for another great year of SSO! #SSO2025